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Patients with symptoms suggestive of acute myocardial infarction (AMI) account for 2 
about 10% of all emergency department (ED) presentations.(1) The majority of 3 
patients are finally found to have diagnoses other than AMI.(2) Thus, the expeditious 4 
evaluation of such patients is important as delays in ruling out AMI may interfere with 5 
the detection of other underlying diseases. The 0/1hour(h)-algorithm and the 0/3h-6 
algorithm are both recommended by the European Society of Cardiology (ESC) with 7 
a class I recommendation for the early rule-out of AMI.(1) The 0/1h- and the 0/3h-8 
algorithm are completely different protocols. While the 0/1h-algorithm uses high-9 
sensitivity cardiac troponin (hs-cTn) concentrations at presentation and absolute 10 
changes within the first hour, and hence takes optimal advantage of the increased 11 
diagnostic accuracy and precision of hs-cTn assays, the 0/3h-algorithm uses a fixed 12 
threshold protocol based on the 99th percentile at presentation and 3h in conjunction 13 
with clinical criteria (Global Registry of Acute Coronary Events (GRACE) score below 14 
140 and the need to be pain-free). It is currently unknown whether one algorithm is 15 
preferable to the other.  16 
The aim of this study was to directly compare safety quantified by the negative 17 
predictive value (NPV) and the negative likelihood ratio (LR) for the presence of AMI, 18 
and efficacy quantified by the proportion of patients triaged towards rule-out in a 19 
large diagnostic multicenter study enrolling patients presenting with suspected AMI to 20 
the ED (NCT00470587). The study was carried out according to the principles of the 21 
Declaration of Helsinki and approved by the local ethics committees. Written 22 
informed consent was obtained from all patients. Patients presenting with ST-23 
Segment-Elevation MI were excluded. Triage towards rule-out by the 0/1h- or the 24 
0/3h-algorithm was compared against the final adjudication performed by two 25 
independent cardiologists using all information including cardiac imaging and serial 26 
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hs-cTnT measurements. Analyses were performed using hs-cTnT and hs-cTnI. NPV 27 
and efficacy were compared using McNemar’s test, respectively Pearson X2 test. 28 
95%-Confidence intervals were calculated using the Wilson score method without 29 
continuity correction.  30 
Among 2547 patients eligible for analysis using hs-cTnT, AMI was the final 31 
adjudicated diagnosis in 387 patients (15%). The 0/1h-algorithm provided similar 32 
safety compared to the 0/3h-algorithm (NPV 99.8% (95%CI 99.4-99.9%) and 33 
negative LR 0.01 (95%CI 0.00-0.03) versus 99.7% (95%CI 99.2-99.9%) and 0.02 34 
(95%CI 0.00-0.05)), but allowed to rule-out significantly more patients as compared 35 
to the 0/3h-algorithm (60% vs. 44%, p<0.001). Among 2197 patients eligible for 36 
analysis using hs-cTnI, AMI was the final diagnosis in 327 patients (15%). The 0/1h-37 
algorithm provided higher safety compared to the 0/3h-algorithm (NPV 99.6% 38 
(95%CI 99.1-99.9%) and negative LR 0.02 (95%CI 0.01-0.05) vs. 97.8% (95%CI 39 
96.7-98.5%) and 0.13 (95%CI 0.09-0.19)), and allowed to rule-out a similar portion of 40 
patients as compared to the 0/3h-algorithm (52% vs. 51%, p=0.507, Figure 1).  41 
Overall, 711 patients (28%) presented within the first two hours from chest 42 
pain onset (CPO). Safety for the 0/1h- and 0/3h-algorithm using hs-cTnT was very 43 
high (NPV 99.6% (95%CI 98.4-99.9%) versus 100% (95%CI 98.9-100%) and 44 
comparable to late presenters (CPO>2h) with 99.9% (95%CI 99.5-100%) versus 45 
99.6% (95%CI 98.9-99.9%), respectively. The 0/1h-algorithm allowed to rule-out 46 
more patients compared to the 0/3h-algorithm in early presenters (64% versus 49% 47 
p<0.001) and in late presenters (59% versus 42%, p<0.001). Findings were 48 
confirmed using hs-cTnI as well as using 30-days survival as an additional outcome 49 
measure for safety with survival rates of 99.9%-100% for patients triaged towards 50 
rule-out by both algorithms. 51 
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These findings corroborate and extend previous work on the development and 52 
validation of safe and effective rule-out strategies for AMI and have important clinical 53 
implications.(3–5) The excellent safety achieved with both algorithms documents the 54 
suitability of most of these patients for early discharge and outpatient management. 55 
Beyond the more favorable combination of safety and efficacy by the 0/1h-algorithm 56 
versus the 0/3h-algorithm, the following features may help physicians and institutions 57 
in the selection of their preferred triage algorithm. First, the 0/1h-algorithm has the 58 
obvious and important additional advantage of allowing clinical decision-making two 59 
hours earlier as compared to the 0/3h-algorithm. As most patients triaged towards 60 
early rule-out are also candidates for direct discharge from the ED, it is very likely 61 
that it will reduce time to discharge and treatment cost in the ED. Second, the 0/1h-62 
algorithm does not require the use of a specific risk score, which further increases its 63 
feasibility. Previous studies have documented that omitting any of the three elements 64 
of the 0/3h-algorithm (hs-cTn, GRACE-score, pain-free criteria) in an effort to simplify 65 
the approach would worsen its safety and is therefore discouraged.(3) When putting 66 
our findings into clinical perspective, it is important to highlight that the 0/1h-algorithm 67 
and the 0/3h-algorithm should always be used in conjunction with all clinical 68 
information available. This is of paramount importance as among patients presenting 69 
with acute chest discomfort to the ED, the rule-out of AMI is related to the possibility 70 
of rapid discharge and outpatient management, but not identical to it.  71 
In conclusion, the 0/1h-algorithm is superior to the 0/3h-algorithm using hs-72 
cTnT as well as hs-cTnI, as it more favorably combines safety with efficacy. 73 
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Figure 1 Direct comparison of the 0/1h- and 0/3h-algorithm for early rule-out of AMI using hs-cTnT (A) and hs-cTnI (B) 
 
 
The figure is illustrating both co-primary endpoints: safety, as quantified by the negative predictive value (%), and efficacy (proportion 
of patients assigned to ruled-out, %). Bars represent 95% confidence intervals, hs-cTn = high sensitivity cardiac troponin. AMI = acute 
myocardial infarction.  
